ProtoKinetix, Incorporated (PKTX)
USD 0.01
(26.5%)
USD 0.01
(26.5%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -48.25 Thousand USD | 17.44% |
| 2022 | -58.45 Thousand USD | -1848.33% |
| 2021 | -3000.00 USD | 0.0% |
| 2020 | -3000.00 USD | 0.0% |
| 2019 | -3000.00 USD | 0.0% |
| 2018 | -3000.00 USD | 0.0% |
| 2017 | -3000.00 USD | 0.0% |
| 2016 | -3000.00 USD | -100.0% |
| 2015 | -1500.00 USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 2000.00 USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 124.00 USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -13.02 Thousand USD | -15.07% |
| 2024 Q1 | -11.31 Thousand USD | -121.72% |
| 2023 Q2 | -11.56 Thousand USD | -8.04% |
| 2023 Q1 | -10.7 Thousand USD | 80.96% |
| 2023 FY | -48.25 Thousand USD | 17.44% |
| 2023 Q3 | -11.18 Thousand USD | 3.25% |
| 2023 Q4 | 52.09 Thousand USD | 565.71% |
| 2022 Q1 | -750.00 USD | 0.0% |
| 2022 Q2 | -750.00 USD | 0.0% |
| 2022 FY | -58.45 Thousand USD | -1848.33% |
| 2022 Q4 | -56.2 Thousand USD | -7393.33% |
| 2022 Q3 | -750.00 USD | 0.0% |
| 2021 FY | -3000.00 USD | 0.0% |
| 2021 Q1 | -750.00 USD | 0.0% |
| 2021 Q2 | -750.00 USD | 0.0% |
| 2021 Q3 | -750.00 USD | 0.0% |
| 2021 Q4 | -750.00 USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | -3000.00 USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | -3000.00 USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | -3000.00 USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | -3000.00 USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | -3000.00 USD | -100.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | -1500.00 USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | 2000.00 USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | -6420.00 USD | -3.73% |
| 2004 Q2 | -6189.00 USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 100.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2001 FY | 124.00 USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.412% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 84.896% |
| Qrons Inc. | - USD | Infinity% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 61.16% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.041% |
| Adynxx, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.813% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 134.348% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1878.639% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.322% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1655.738% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.493% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 173.422% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -41.315% |
| Mesoblast Limited | -35.16 Million USD | 99.863% |
| Marizyme, Inc. | 457.7 Thousand USD | 110.544% |
| Genus plc | 178.7 Million USD | 100.027% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.022% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 177.554% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 111.766% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -338.718% |
| ContraFect Corporation | -154 Thousand USD | 68.663% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 3.482% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 162.869% |
| IMV Inc. | -962.29 Thousand USD | 94.985% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 87.546% |
| MultiCell Technologies, Inc. | 49.32 USD | 97948.743% |
| ONE Bio Corp. | 20.12 Million USD | 100.24% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.12% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 198.689% |
| Q BioMed Inc. | -8988.00 USD | -436.927% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.171% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -212.883% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.109% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 95.773% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 168.941% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -874.536% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 50.511% |
| GB Sciences, Inc. | -624.00 USD | -7633.814% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 43.903% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -23101.442% |
| Enzolytics Inc. | 30.7 Thousand USD | 257.154% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 110.003% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.004% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 90.62% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 107.817% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.012% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -444.93% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 42.445% |
| Kadimastem Ltd | -630.13 Thousand USD | 92.342% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 104.885% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.502% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.313% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -307.765% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 127.333% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 127.333% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 103.556% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -66.41% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 110.723% |
| SYBLEU INC | 11.69 Thousand USD | 512.611% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 101.047% |
| Bioxytran, Inc. | -8285.00 USD | -482.486% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 87.062% |
| Neutra Corp. | 14.33 Thousand USD | 436.652% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 41.148% |
| PureTech Health plc | -1.6 Million USD | 96.989% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 95.18% |
| IXICO plc | 3.27 Million USD | 101.476% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 93.046% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 97.305% |
| CSL Limited | 7.7 Billion USD | 100.001% |
| Cellectis S.A. | 18 Thousand USD | 368.106% |